Discover
OKUR
OnKure Therapeutics, Inc.
2.41
2 x 3.02
2 x 5.32
bid
ask
+
0.11
4.78%
2 @ 06:09 PM
2.43 +0.02 (0.83%)
| Ytd | -16.90% | |
| 1y | -23.00% |
2.25
day range
2.42
2.30
52 week range
5.27
| Open | 2.29 | Prev Close | 2.30 | Low | 2.25 | High | 2.42 | Mkt Cap | 97.35M |
| Vol | 609.37K | Avg Vol | 216.96K | EPS | -3.20 | P/E | N/A | Forward P/E | -2.64 |
| Beta | 0.12 | Short Ratio | 19.81 | Inst. Own | 53.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 3.43 | 200-d Avg | 3.65 | 1yr Est | 34.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.97 | -1.1 | -0.13 | -13.40% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-05 | Leerink Partners | Upgrade | Outperform | |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-10 | Oppenheimer | Upgrade | Outperform |
Profile
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-03 | CARRUTHERS R MICHAEL | Director | 4.94K | Stock Award(Grant) |
| 2023-07-25 | GREY MICHAEL G. | Officer and Director | 628.85K | Stock Gift |
| 2023-08-27 | HALL ASHLEY | Officer | 39.60K | Conversion of Exercise of derivative security |
| 2024-09-24 | LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-10-03 | LEVERONE JASON A. CPA | Chief Financial Officer | 16.33K | Stock Award(Grant) |
| 2023-06-22 | NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | 3.33M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | NEA Management Company, LLC | 478.55K | 3.91M | 3.78% |
| 2024-09-29 | BML Capital Management, LLC | 345.74K | 2.83M | 2.73% |
| 2024-09-29 | Highbridge Capital Management, LLC. | 306.27K | 2.51M | 2.42% |
| 2024-09-29 | Tang Capital Management, LLC | 294.63K | 2.41M | 2.33% |
| 2024-09-29 | Carlyle Group Inc. | 269.90K | 2.21M | 2.13% |
| 2024-09-29 | Rivervest Venture Management LLC | 253.42K | 2.07M | 2.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | iShares Biotechnology ETF | 64.80K | 530.02K | 0.51% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 59.61K | 487.62K | 0.47% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 27.85K | 227.85K | 0.22% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 10.54K | 86.18K | 0.08% |
| 2024-10-30 | iShares Micro Cap ETF | 4.61K | 37.74K | 0.04% |
| 2024-10-30 | Fidelity Total Market Index Fund | 3.60K | 29.44K | 0.03% |